AngioDynamics, Inc. $ANGO Holdings Lifted by Acuitas Investments LLC

Acuitas Investments LLC increased its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 12.7% during the 3rd quarter, Holdings Channel.com reports. The fund owned 498,530 shares of the medical instruments supplier’s stock after purchasing an additional 56,300 shares during the quarter. AngioDynamics comprises about 3.6% of Acuitas Investments LLC’s portfolio, making the stock its 5th biggest position. Acuitas Investments LLC’s holdings in AngioDynamics were worth $5,569,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. State of Wyoming boosted its stake in AngioDynamics by 53.6% in the third quarter. State of Wyoming now owns 4,749 shares of the medical instruments supplier’s stock valued at $53,000 after acquiring an additional 1,658 shares in the last quarter. State of Alaska Department of Revenue purchased a new stake in shares of AngioDynamics in the 3rd quarter valued at about $25,000. Washington Trust Advisors Inc. purchased a new stake in shares of AngioDynamics in the 3rd quarter valued at about $27,000. Rhumbline Advisers boosted its position in shares of AngioDynamics by 4.3% in the 2nd quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock valued at $608,000 after purchasing an additional 2,510 shares during the period. Finally, Invesco Ltd. boosted its position in shares of AngioDynamics by 2.2% in the 2nd quarter. Invesco Ltd. now owns 122,596 shares of the medical instruments supplier’s stock valued at $1,216,000 after purchasing an additional 2,667 shares during the period. Institutional investors and hedge funds own 89.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on ANGO. Zacks Research raised AngioDynamics from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a report on Wednesday, January 21st. Finally, Wall Street Zen lowered shares of AngioDynamics from a “buy” rating to a “hold” rating in a research report on Sunday, December 21st. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $19.33.

AngioDynamics Stock Up 0.4%

Shares of ANGO opened at $10.71 on Wednesday. AngioDynamics, Inc. has a 52-week low of $8.36 and a 52-week high of $13.99. The company has a 50-day simple moving average of $10.73 and a 200-day simple moving average of $11.54. The company has a market capitalization of $441.47 million, a PE ratio of -15.98 and a beta of 0.48.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.